Voyager Therapeutics Inc (NASDAQ:VYGR) insider Bernard Ravina sold 3,630 shares of the firm’s stock in a transaction dated Wednesday, January 10th. The stock was sold at an average price of $16.40, for a total value of $59,532.00. Following the sale, the insider now directly owns 7,353 shares of the company’s stock, valued at $120,589.20. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Bernard Ravina also recently made the following trade(s):

  • On Monday, December 11th, Bernard Ravina sold 5,490 shares of Voyager Therapeutics stock. The stock was sold at an average price of $13.63, for a total value of $74,828.70.
  • On Friday, November 10th, Bernard Ravina sold 5,490 shares of Voyager Therapeutics stock. The stock was sold at an average price of $13.26, for a total value of $72,797.40.

Voyager Therapeutics Inc (VYGR) opened at $18.38 on Monday. Voyager Therapeutics Inc has a one year low of $8.10 and a one year high of $25.99. The firm has a market capitalization of $578.04, a P/E ratio of -6.47 and a beta of 3.89.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Thursday, November 2nd. The company reported ($0.89) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.72) by ($0.17). Voyager Therapeutics had a negative net margin of 1,195.63% and a negative return on equity of 65.50%. equities analysts anticipate that Voyager Therapeutics Inc will post -2.99 EPS for the current year.

VYGR has been the subject of a number of recent research reports. Chardan Capital reaffirmed a “hold” rating and set a $17.00 price target on shares of Voyager Therapeutics in a research note on Tuesday, October 31st. Canaccord Genuity initiated coverage on Voyager Therapeutics in a research note on Friday, October 27th. They set a “buy” rating and a $35.00 price target for the company. Zacks Investment Research raised Voyager Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, January 6th. ValuEngine raised Voyager Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 30th. Finally, Raymond James Financial initiated coverage on Voyager Therapeutics in a research note on Thursday, October 12th. They set an “outperform” rating and a $35.00 price target for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and twelve have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $26.90.

Hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp raised its stake in shares of Voyager Therapeutics by 20.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 53,225 shares of the company’s stock valued at $477,000 after acquiring an additional 9,207 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Voyager Therapeutics by 3.2% in the 2nd quarter. Vanguard Group Inc. now owns 430,765 shares of the company’s stock valued at $3,860,000 after acquiring an additional 13,194 shares in the last quarter. Wells Fargo & Company MN raised its stake in shares of Voyager Therapeutics by 312.8% in the 3rd quarter. Wells Fargo & Company MN now owns 377,190 shares of the company’s stock valued at $7,766,000 after acquiring an additional 285,806 shares in the last quarter. Citadel Advisors LLC bought a new position in shares of Voyager Therapeutics in the 3rd quarter valued at approximately $5,155,000. Finally, Point72 Asset Management L.P. bought a new position in shares of Voyager Therapeutics in the 3rd quarter valued at approximately $2,695,000. 35.97% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://theolympiareport.com/2018/01/15/bernard-ravina-sells-3630-shares-of-voyager-therapeutics-inc-vygr-stock.html.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.